Eovist

Magnetic Resonance Angiography, MRI, Chronic Liver Diseases (CLD)

Treatment

2 FDA approvals

20 Active Studies for Eovist

What is Eovist

Gadoxetic acid

The Generic name of this drug

Treatment Summary

Gadoxetic acid is a contrast agent used for intravenous injection. It is made up of a gadolinium ion complexed with an ethoxybenzyl diethylenetriaminepentaacetic acid moiety. This drug is produced by Bayer HealthCare Pharmaceuticals and was approved by the FDA in 2008.

Eovist

is the brand name

Eovist Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Eovist

Gadoxetic acid

2008

1

Approved as Treatment by the FDA

Gadoxetic acid, also known as Eovist, is approved by the FDA for 2 uses including MRI and Chronic Liver Diseases (CLD) .

MRI

Chronic Liver Diseases (CLD)

Effectiveness

How Eovist Affects Patients

Gadoxetate disodium is a two-part drug that is both hydrophilic (water-loving) and lipophilic (fat-loving). After injection, it spreads throughout the body, then is taken up by the liver cells specifically.

How Eovist works in the body

When gadoxetate disodium is exposed to a strong magnetic field, it creates a magnetic field of its own around the tissue. This disturbs the protons in the nearby water and changes their properties, which can be detected by a special device.

When to interrupt dosage

The suggested measure of Eovist relies upon the identified disorder, including Chronic Liver Diseases (CLD), Magnetic Resonance Angiography and MRI Scan. The amount of dosage is contingent upon the method of delivery (e.g. Solution - Intravenous or Intravenous) enumerated in the table beneath.

Condition

Dosage

Administration

Magnetic Resonance Angiography

, 181.43 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution - Intravenous, Solution

MRI

, 181.43 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution - Intravenous, Solution

Chronic Liver Diseases (CLD)

, 181.43 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution - Intravenous, Solution

Warnings

Eovist has one contraindication and must not be employed when encountering the circumstances given in the following table.

Eovist Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Common Eovist Drug Interactions

Drug Name

Risk Level

Description

Eovist Toxicity & Overdose Risk

The toxic dose of the drug for rats when taken orally is 18100mg/kg, for mice is 14500mg/kg, and for dogs is more than 2200mg/kg. The toxic dose of the drug for rats when taken intravenously ranges from 3600 - 7300mg/kg, and for mice ranges from 5400 - 10900mg/kg.

Eovist Novel Uses: Which Conditions Have a Clinical Trial Featuring Eovist?

13 active trials are currently assessing the potential of Eovist for use in Magnetic Resonance Imaging (MRI) Scans, Magnetic Resonance Angiography and the management of Chronic Liver Diseases (CLD).

Condition

Clinical Trials

Trial Phases

Magnetic Resonance Angiography

0 Actively Recruiting

MRI

17 Actively Recruiting

Phase 2, Not Applicable, Phase 3

Chronic Liver Diseases (CLD)

3 Actively Recruiting

Phase 4, Not Applicable

Patient Q&A Section about eovist

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the difference between gadavist and Eovist?

"Gadavist and Eovist are available as sterile solutions that are injected intravenously. Gadavist is a macrocyclic gadolinium-based contrast agent, while Eovist is a linear gadolinium-based contrast agent."

Answered by AI

What is an Eovist enhanced MRI?

"EOVIST is a contrast agent that helps magnetic resonance imaging (MRI) machines take clearer pictures of the liver. It is only for use in adults who are suspected of having liver disease. The contrast agent is injected intravenously."

Answered by AI

When is Eovist used in MRI?

"This medication is injected into veins and is used during MRI scans to get a better look at the liver and any lesions or damage present. It is for people who are known to have liver disease or those who are suspected of having liver disease."

Answered by AI

Is Eovist the same as gadolinium?

"Eovist is a gadolinium-based contrast agent (GBCA) that is injected into your vein and used with a magnetic resonance imaging (MRI) scanner. An MRI exam with a GBCA helps your doctor to see problems better than an MRI exam without a GBCA."

Answered by AI

Clinical Trials for Eovist

Image of University of Washington Medical Center in Seattle, United States.

Copper Supplementation for Liver Cirrhosis

18+
All Sexes
Seattle, WA

End stage liver disease or cirrhosis is a major cause of mortality in the United States and the world. Other than targeting the underlying cause, such as alcohol cessation and antiviral therapy, very few medical treatments can change the natural history of cirrhosis. Malnutrition is one of the few potentially modifiable factors that have been associated with cirrhosis severity and poor prognosis. The transition metal copper (Cu) is an essential trace metal that must be acquired from diet. Its metabolism is primarily regulated by the liver in its role as a master regulator of nutrients. In 2019, the investigators reported that Cu deficiency defined by below normal serum or liver concentrations occurred in a wide range of liver disorders and was associated with a severe disease phenotype. Improvement in liver function was observed in 2 of the 3 patients who received Cu supplementation. In 2023, the investigators conducted a longitudinal cohort study utilizing clinical, serum and liver explant tissue data from 183 cirrhosis patients. The investigators showed that Cu deficiency was associated with 2-fold higher infection rate and a more than 3-fold increase in the risk of death compared to patients with normal Cu status. These preliminary findings and the well-established importance of Cu in human health prompted the investigators to design the current pilot randomized, placebo-controlled, crossover trial to determine the effect of Cu supplementation on Cu dependent biochemical changes, patient safety and patient reported outcomes in cirrhosis.

Recruiting
Has No Placebo

University of Washington Medical Center

Lei Yu, MD

Image of The Mind Research Network in Albuquerque, United States.

Carbon Dioxide for Traumatic Brain Injury

18 - 82
All Sexes
Albuquerque, NM

The current study tests whether different exposures to carbon dioxide (CO2) can safely result in the increased movement of proteins from the brain into the blood. The investigators believe that this would be a proxy for the brain clearing waste products more effectively. The current study will use a counter-balanced design, in which individuals with and without a history of traumatic brain injury (TBI) will receive different levels of CO2 (targeted changes of approximately 5 or 10 mmHG in end-tidal CO2) approximately one week apart. The counter-balanced design means that each participant receives a single dose of CO2 at each visit, and different doses of CO2 at each visit. The order in which participants receive the dose is randomized, and the participant will not be informed of the dose.

Recruiting
Has No Placebo

The Mind Research Network

Andrew R Mayer, Phd

Image of University of California, San Francisco in San Francisco, United States.

Breath-Holding Techniques for Improved Liver MRI

18 - 75
All Sexes
San Francisco, CA

The goal of this interventional study (clinical trial) is to learn if different breath-holding techniques, with and without extra oxygen, can improve the quality of abdominal Magnetic Resonance Imaging (MRI) images in healthy adults, ages 18-75. The main questions it aims to answer are: * Does breath-holding at end-expiration improve image quality in abdominal MRI scans? * Does adding oxygen while breath-holding further reduce motion artifacts in abdominal MRI scans? Researchers will compare breath-holding with and without oxygen to see if using oxygen improves image quality during MRI scans. Participants will: * Be pre-screened for MRI safety and trained on breath-hold procedures * Have one non-contrast abdominal MRI scan at the University of California San Francisco (UCSF) China Basin Imaging Center * Use two different breath-holding techniques during the scan, with and without oxygen * Complete one study visit lasting about 45 minutes to 1 hour

Recruiting
Has No Placebo

University of California, San Francisco

John P Roberts, MD

Have you considered Eovist clinical trials?

We made a collection of clinical trials featuring Eovist, we think they might fit your search criteria.
Go to Trials

Have you considered Eovist clinical trials?

We made a collection of clinical trials featuring Eovist, we think they might fit your search criteria.
Go to Trials

Have you considered Eovist clinical trials?

We made a collection of clinical trials featuring Eovist, we think they might fit your search criteria.
Go to Trials